中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 11
Nov.  2017
Turn off MathJax
Article Contents

Primary biliary cholangitis:opportunities and challenges

DOI: 10.3969/j.issn.1001-5256.2017.11.001
Research funding:

 

  • Received Date: 2017-10-11
  • Published Date: 2017-11-20
  • Primary biliary cholangitis (PBC) is an autoimmune liver disease mainly involving the interlobular bile ducts and can progress to liver cirrhosis and liver failure.Early diagnosis and management can significantly improve the prognosis of such patients and their quality of life.This article focuses on the achievements of PBC research and related difficult issues in China, with reference to the clinical practice guidelines for PBC by European Association for the Study of the Liver in 2017 and experience in clinical practice.

     

  • loading
  • [1]BEUERS U, GERSHWIN ME, GISH RG, et al.Changing nomenclature for PBC:from cirrhosis to cholangitis[J].J Hepatol, 2015, 13 (11) :1867-1869.
    [2]SHUAI Z, WANG J, BADAMAGUNTA M, et al.The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis[J].Hepatology, 2017, 65 (5) :1670-1682.
    [3]European Association for the Study of the Liver.EASL clinical practice guidelines:the diagnosis and management of patients with primary biliary cholangitis[J].J Hepatol, 2017, 67 (1) :145-172.
    [4]DAHLQVIST G, GAOUAR F, CARRAT F, et al.Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis[J].Hepatology, 2017, 65 (1) :152-163.
    [5]CARBONE M, SHARP SJ, FLACK S, et al.The UK-PBC risk scores:derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis[J].Hepatology, 2016, 63 (3) :930-950.
    [6]LAMMERS WJ, HIRSCHFIELD GM, CORPECHOT C, et al.Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J].Gastroenterology, 2015, 149 (7) :1804-1812.
    [7]YANG F, YANG Y, WANG Q, et al.The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis:the additional effect of anti-gp210[J].Aliment Pharmacol Ther, 2017, 45 (5) :733-743.
    [8]YANG F, YANG Y, TANG R, et al.Editorial:scoring systems in primary biliary cholangitis-time to make a move.Authors'reply[J].Aliment Pharmacol Ther, 2017, 45 (8) :1164-1165.
    [9]NEVENS F, ANDREONE P, MAZZELLA G, et al.A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J].N Engl J Med, 2016, 375 (7) :631-643.
    [10]SAMUR S, KLEBANOFF M, BANKEN R, et al.Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis[J].Hepatology, 2017, 65 (3) :920-928.
    [11]WANG Q, YANG F, MIAO Q, et al.The clinical phenotypes of autoimmune hepatitis:a comprehensive review[J].J Autoimmun, 2016, 66:98-107.
    [12]YANG F, WANG Q, WANG Z, et al.The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis[J].Clin Rev Allergy Immunol, 2016, 50 (1) :114-123.
    [13]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association;Chinese Society of Infectious Diseases, Chinese Medical Association.Consensus on the diagnosis and management of primary biliary cirrhosis (cholangitis) (2015) [J].J Clin Hepatol, 2015, 31 (12) :1980-1988. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会.原发性胆汁性肝硬化 (又名原发性胆汁性胆管炎) 诊断和治疗共识 (2015) [J].临床肝胆病杂志, 2015, 31 (12) :1980-1988.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (304) PDF downloads(272) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return